Purpose Precision medicine has been most successful in targeting single mutations, but
personalized medicine using broader genomic tumor profiles for individual patients is less …

Background and purpose We aimed to develop a clinically applicable prognosis prediction
model predicting overall survival (OS) and progression-free survival (PFS) for glioblastoma …

Background Glioblastoma (GBM) is the most common malignant brain tumor in adults. The
prognosis of GBM patients is poor. Even with active standard treatment, the median overall …

Purpose To optimize and validate a current (NRG [a newly constituted National Clinical
Trials Network group through National Surgical Adjuvant Breast and Bowel Project [NSABP] …

Background A randomized trial in glioblastoma patients with methylated-MGMT (m-MGMT)
found an improvement in median survival of 16.7 months for combination therapy with …

Importance There is a need for a more refined, molecularly based classification model for
glioblastoma (GBM) in the temozolomide era. Objective To refine the existing clinically …

Objective Several survival prediction models for patients with glioblastoma have been
proposed, but none is widely used. This study aims to identify the predictors of overall …

Background This study focused on minimizing the costs and toxic effects associated with
unnecessary chemotherapy. We sought to optimize the adjuvant therapy strategy, choosing …

Purpose Despite the intra-and intertumoral heterogeneity seen in glioblastoma multiforme
(GBM), there is little definitive data on the underlying cause of the differences in patient …

Background Glioblastoma patients administered standard therapies, comprising maximal
surgical resection, radiation therapy with concomitant and adjuvant temozolomide, have a …